Aethlon Medical(AEMD) - 2025 Q3 - Quarterly Results

Financial Performance - Aethlon Medical reported a cash balance of approximately $4.8 million as of December 31, 2024[15]. - Consolidated operating expenses decreased by approximately $1.8 million, or 50%, to $1.8 million compared to $3.6 million for the same quarter in 2023[16]. - The net loss for the fiscal quarter ended December 31, 2024, decreased to approximately $1.8 million from approximately $3.5 million in the same quarter of 2023[20]. - Net loss for the three months ended December 31, 2024, was $1,754,783, compared to a net loss of $3,466,121 for the same period in 2023, showing a reduction of approximately 49.3%[31]. - Basic and diluted loss per share improved from $(1.37) to $(0.13) for the three months ended December 31, 2024, indicating a significant reduction in loss per share[31]. - Interest income for the three months ended December 31, 2024, was $59,964, compared to $100,967 in the same period of 2023, a decrease of approximately 40.5%[31]. - Accumulated deficit increased from $(161,699,924) to $(154,566,728), indicating a reduction in the deficit by about 4.4%[29]. Clinical Trials and Research - The company has enrolled three patients in its Hemopurifier cancer trial, with one patient successfully treated[3]. - Aethlon has implemented strategic cost-cutting measures to enhance operational efficiency, focusing on high-impact oncology trials in Australia and India[9]. - The company received ethics committee approval for protocol amendments at all three clinical sites in Australia, facilitating improved patient enrollment[6]. - The protocol amendment allows for enrolling patients only after confirming non-responsiveness to anti-PD-1 therapy, streamlining the trial process[5]. - Approximately 30% of patients receiving pembrolizumab or nivolumab have lasting clinical responses, highlighting the need for improved treatment options[12]. - The Hemopurifier is designed to remove extracellular vesicles (EVs) from the bloodstream, potentially improving therapeutic responses to anti-PD-1 antibodies[12]. - Aethlon is pursuing approval for a similar clinical trial in India, with HREC approval obtained at Medanta Medicity Hospital[7]. Financial Position - Total current assets increased from $4,968,407 to $6,225,788, representing a growth of approximately 25.3%[29]. - Total liabilities rose from $2,191,193 to $2,479,650, an increase of about 13.1%[29]. - Total stockholders' equity increased from $4,334,166 to $5,766,332, representing an increase of about 32.9%[29]. - Total assets grew from $6,525,359 to $8,245,982, an increase of approximately 26.3%[29]. - Total operating expenses decreased from $3,567,088 to $1,814,747, a decline of about 49.1% year-over-year for the three-month period[31]. - Cash and cash equivalents increased from $4,825,387 to $5,441,978, reflecting a growth of approximately 12.8%[29].